Regulatory Submission Planning Playbook

Chapter 1. Regulatory Submission Planning: What Must Be Managed

1.1 The Role of Submission Planning in Drug and Biologics Development
1.2 Differences Among IND, NDA, and BLA Submissions
1.3 Core Submission Workstreams: Clinical, Nonclinical, CMC, Regulatory, Quality, Safety, and Publishing
1.4 Common Failure Modes: Late Data, Unstable Labeling, CMC Gaps, Weak Governance, and Publishing Surprises
1.5 Submission Planning Checklist: What Must Be True Before Launch of the Submission Effort

Chapter 2. Defining the Submission Strategy and Regulatory Pathway

2.1 Clarifying the Target Filing: Indication, Population, Product Presentation, and Regulatory Objective
2.2 Mapping the Regulatory Pathway: Standard Review, Priority Review, Accelerated Approval, Orphan, Breakthrough, Fast Track, and Rolling Review
2.3 Defining the Target Product Profile and Draft Labeling Strategy
2.4 Building the Health Authority Interaction Plan: Pre-IND, End-of-Phase 2, Pre-NDA/BLA, Type C, and Scientific Advice Meetings
2.5 Submission Strategy Template: Key Decisions, Assumptions, Risks, and Open Questions

Chapter 3. Building the End-to-End Submission Plan

3.1 Designing the Integrated Submission Roadmap From Data Lock to Filing Acceptance
3.2 Building the Master Timeline: Authoring, Review, QC, Publishing, Validation, and Filing Milestones
3.3 Defining Workstreams, Owners, Dependencies, and Decision Rights
3.4 Setting Up Governance: Submission Leadership Team, Issue Escalation, Weekly Control Tower, and Executive Steering Committee
3.5 Submission Planning Tools: Integrated Gantt, Dependency Tracker, Risk Register, and Milestone Dashboard

Chapter 4. Content Architecture for IND, NDA, and BLA Submissions

4.1 Overview of the Common Technical Document and eCTD Structure
4.2 Module 1: Regional Administrative Information and Prescribing Information
4.3 Module 2: Summaries and Overviews, Including Clinical, Nonclinical, and Quality Summaries
4.4 Modules 3, 4, and 5: CMC, Nonclinical Study Reports, Clinical Study Reports, Datasets, and Integrated Analyses
4.5 Content Map Template: Document Inventory, Source Data, Authors, Reviewers, and Readiness Status

Chapter 5. Managing the Authoring Workflow

5.1 Designing the Authoring Model: Internal Authors, Medical Writers, Functional Reviewers, and Accountable Owners
5.2 Creating Document Standards: Shells, Style Guides, Data Presentation Rules, Reference Conventions, and QC Expectations
5.3 Running Review Cycles: Scientific Review, Regulatory Review, Quality Review, Legal Review, and Final Approval
5.4 Managing Cross-Document Consistency: Labeling, Claims, Safety Language, Efficacy Endpoints, CMC Descriptions, and Population Definitions
5.5 Authoring Workflow Toolkit: RACI, Document Tracker, Review Calendar, Comment Adjudication Log, and Finalization Checklist

Chapter 6. Data, Quality, and Submission Readiness

6.1 Critical Data Dependencies: Database Lock, Tables/Listings/Figures, Integrated Summaries, Safety Updates, and CMC Release Data
6.2 Ensuring Inspection Readiness and Traceability From Source Data to Submission Claims
6.3 Quality Control Process: Technical QC, Data QC, Reference QC, Hyperlink QC, and Formatting QC
6.4 Managing Late-Breaking Changes, Data Cuts, Protocol Deviations, Safety Updates, and Labeling Revisions
6.5 Filing Readiness Checklist: Content Complete, Data Reconciled, Quality Cleared, Publishing-Ready

Chapter 7. eCTD Assembly, Publishing, Filing, and Review Cycles

7.1 Overview of eCTD Publishing Requirements and Sequence Management
7.2 Preparing Submission-Ready Documents: PDF Standards, Bookmarks, Hyperlinks, Granularity, Lifecycle Operators, and Metadata
7.3 Running Publishing, Validation, and Technical QC
7.4 Filing Logistics: Gateway Submission, Acknowledgments, Filing Review, Information Requests, and 74-Day Letter / Filing Communication
7.5 Managing Post-Submission Review: FDA Information Requests, Major Amendments, Advisory Committee Preparation, Labeling Negotiation, and Approval Readiness

Chapter 8. Working With External Advisors and Consultants

8.1 When to Bring in External Support: Capacity Gaps, Experience Gaps, Acceleration Needs, and Independent Quality Review
8.2 Types of Advisors: Regulatory Strategists, Medical Writers, CMC Experts, Clinical Development Experts, Biostatisticians, Publishing Vendors, and Quality Consultants
8.3 Working With Large Consulting Firms: Best-Fit Situations, Advantages, Limitations, and Cost Considerations
8.4 Working With Independent Management Consultants Through Umbrex: Use Cases, Staffing Models, and How to Integrate Them With the Internal Team
8.5 Advisor Selection Checklist: Expertise, Submission Experience, Therapeutic-Area Knowledge, Availability, Operating Model, and References